Costs and resource utilization for diagnosis and treatment during the initial year in a european inflammatory bowel disease inception cohort: An ECCO-EpiCom study

Inflammatory Bowel Diseases

Volumn 21, Issue 1, 2015, Pages 121-131

  Burisch, Johan ^a   Vardi, Hillel ^b   Pedersen, Natalia ^a   Brinar, Marko ^c   Cukovic Cavka, Silvja ^c   Kaimakliotis, Ioannis ^d   Duricova, Dana ^e   Bortlik, Martin ^e   Shonová, Olga ^d   Vind, Ida ^f   Avnstrøm, Søren ^f   Thorsgaard, Niels ^g   Krabbe, Susanne ^h   Andersen, Vibeke ^h,i,j   Dahlerup, Jens F ^k   Kjeldsen, Jens ^l   Salupere, Riina ^m   Olsen, Jóngero ^d   Nielsen, Kári R ^d   Manninen, Pia ⁿ   Collin, Pekka ⁿ   Katsanos, Konstantinnos H ^o   Tsianos, Epameinondas V ^o   Ladefoged, Karin ^p   Lakatos, Laszlo ^q   Bailey, Yvonne ^r   O'Morain, Colm ^r   Schwartz, Doron ^b   Lupinacci, Guido ^d,s   De Padova, Angelo ^d,t   Jonaitis, Laimas ^u   Kupcinskas, Limas ^u   Turcan, Svetlana ^v   Barros, Louisa ^d   Magro, Fernando ^w,x,y   Lazar, Daniela ^z   Goldis, Adrian ^z   Nikulina, Inna ^aa   Belousova, Elena ^aa   Fernandez, Alberto ^ab   Pineda, Juan R ^ac   Almer, Sven ^ad   Halfvarson, Jonas ^ae,af   Tsai, Her Hsin ^ag   Sebastian, Shaji ^ag   Friger, Michael ^b   Greenberg, Dan ^b   Lakatos, Peter L ^q   Langholz, Ebbe ^a   Odes, Selwyn ^b   Munkholm, Pia ^a   more..

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^c UNIVERSITY OF ZAGREB   (Croatia)

^d Private Practice ^*  (Portugal)

^e CHARLES UNIVERSITY   (Czech Republic)

^f AMAGER HOSPITAL   (Denmark)

^g HERNING HOSPITAL   (Denmark)

^h VIBORG HOSPITAL   (Denmark)

ⁱ Hospital of Southern Jutland   (Denmark)

^j UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^k AARHUS UNIVERSITY HOSPITAL   (Denmark)

^l ODENSE UNIVERSITY HOSPITAL   (Denmark)

^m TARTU UNIVERSITY HOSPITAL   (Estonia)

ⁿ TAMPERE UNIVERSITY HOSPITAL   (Finland)

^o UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^p Dronning Ingrids Hospital   (Greenland)

^q SEMMELWEIS UNIVERSITY   (Hungary)

^r ADELAIDE AND MEATH HOSPITAL   (Ireland)

^s MAGGIORE HOSPITAL   (Italy)

^t MORGAGNI PIERANTONI HOSPITAL   (Italy)

^u LITHUANIAN UNIVERSITY OF HEALTH SCIENCES   (Lithuania)

^v STATE UNIVERSITY OF MEDICINE AND PHARMACY NICOLAE TESTEMITANU   (Moldova)

^w HOSPITAL DE SÃO JOÃO   (Portugal)

^x Institute of Pharmacology and Therapeutics Oporto Medical School   (Portugal)

^y UNIVERSITY OF PORTO   (Portugal)

^z VICTOR BABES UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^aa M F VLADIMIRSKY MOSCOW REGIONAL RESEARCH CLINICAL INSTITUTE   (Russian Federation)

^ab HOSPITAL POVISA   (Spain)

^ac UNIVERSITY HOSPITAL COMPLEX OF VIGO   (Spain)

^ad KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^ae ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^af ÖREBRO UNIVERSITY   (Sweden)

^ag HULL ROYAL INFIRMARY   (United Kingdom)

more..

Author keywords

Crohn's disease; Economics of IBD therapies; Epidemiology; Outcomes research; Ulcerative colitis

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE;

ADULT; AGED; ARTICLE; BIOLOGICAL THERAPY; CLINICAL ASSESSMENT; CLINICAL STUDY; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CROHN DISEASE; DISEASE COURSE; DRUG SUBSTITUTION; FEMALE; FOLLOW UP; GASTROINTESTINAL ENDOSCOPY; GASTROINTESTINAL SURGERY; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; IMMUNOMODULATION; IMMUNOTHERAPY; INCIDENCE; INFLAMMATORY BOWEL DISEASE; INFLAMMATORY BOWEL DISEASE UNCLASSIFIED; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; POPULATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; ULCERATIVE COLITIS; ADOLESCENT; CLINICAL TRIAL; ECONOMICS; EUROPE; HEALTH CARE PLANNING; INFLAMMATORY BOWEL DISEASES; MIDDLE AGED; MULTICENTER STUDY; PROGNOSIS; QUESTIONNAIRE; TIME; TRENDS; UTILIZATION; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; EUROPE; FEMALE; FOLLOW-UP STUDIES; HEALTH CARE COSTS; HEALTH RESOURCES; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; PROGNOSIS; QUESTIONNAIRES; TIME FACTORS; YOUNG ADULT;

EID: 84925827444     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000250     Document Type: Article

References (37)

1. Burisch J. Crohn's disease and ulcerative colitis. Occurrence, course and prognosis during the first year of disease in a European population-based inception cohort. Dan Med J. 2014;61:B4778.
2. Bernstein CN, Papineau N, Zajaczkowski J, et al. Direct hospital costs for patients with inflammatory bowel disease in a Canadian tertiary care university hospital. Am J Gastroenterol. 2000;95:677-683.
3. Silverstein MD, Loftus EV, Sandborn WJ, et al. Clinical course and costs of care for Crohn's disease: Markov model analysis of a population-based cohort. Gastroenterology. 1999;117:49-57.
4. Cohen RD, Larson LR, Roth JM, et al. The cost of hospitalization in Crohn's disease. Am J Gastroenterol. 2000;95:524-530.
5. Odes S, Vardi H, Friger M, et al. Cost analysis and cost determinants in a European inflammatory bowel disease inception cohort with 10 years of follow-up evaluation. Gastroenterology. 2006;131:719-728.
6. Burisch J, Jess T, Martinato M, et al. The burden of inflammatory bowel disease in Europe. J Crohns Colitis. 2013;7:322-337.
7. Odes S. How expensive is inflammatory bowel disease? A critical analysis. World J Gastroenterol. 2008;14:6641-6647.
8. Stockbrügger R, Russel M, van Blankenstein M, et al. EC-IBD: a European effort in inflammatory bowel disease. Eur J Intern Med. 2000;11:187-190.
9. van der Valk ME, Mangen MJJ, Leenders M, et al. Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFa therapy: results from the COIN study. Gut. 2014;63:72-79.
10. Burisch J, Pedersen N, Cukovi c- Cavka S, et al. East-West gradient in the incidence of inflammatory bowel disease in Europe: the ECCO-EpiCom inception cohort. Gut. 2014;63:588-597.
11. Burisch J, Pedersen N, Cukovic-Cavka S, et al. Initial disease course and treatment in an inflammatory bowel disease inception cohort in europe: the ECCO-EpiCom cohort. Inflamm Bowel Dis. 2014;20:36-46.
12. Munkholm P. Crohn's disease-occurrence, course and prognosis. An epidemiologic cohort-study. Dan Med Bull. 1997;44:287-302.
13. Langholz E. Ulcerative colitis. An epidemiological study based on a regional inception cohort, with special reference to disease course and prognosis. Dan Med Bull. 1999;46:400-415.
14. Burisch J, Cukovic-Cavka S, Kaimakliotis I, et al. Construction and validation of a web-based epidemiological database for inflammatory bowel diseases in Europe an EpiCom study. J Crohns Colitis. 2011;5:342-349.
15. The Danish Ministry of Health. Charges 2013. Available at: http://www. ssi.dk/Sundhedsdataogit/Sundhedsoekonomi/Takster/Takster 2013.aspx. Accessed May 1, 2013.
16. Pharmacy of the Capital Region of Denmark. Prices for medicine 2013. Available at: http://www.apoteket-regionh.dk. Accessed April 28, 2013.
17. Danmarks Nationalbank. Danmarks Nationalbank-Statistikbank. 2013. Available at: http://nationalbanken.statistikbank.dk. Accessed July 1, 2013.
18. Vind I, Riis L, Jess T, et al. Increasing incidences of inflammatory bowel disease and decreasing surgery rates in Copenhagen City and County, 2003-2005: a population-based study from the Danish Crohn colitis database. Am J Gastroenterol. 2006;101:1274-1282.
19. Langholz E, Munkholm P, Krasilnikoff PA, et al. Inflammatory bowel diseases with onset in childhood. Clinical features, morbidity, and mortality in a regional cohort. Scand J Gastroenterol. 1997;32:139-147.
20. Auvin S, Molinié F, Gower-Rousseau C, et al. Incidence, clinical presentation and location at diagnosis of pediatric inflammatory bowel disease: a prospective population-based study in northern France (1988-1999). J Pediatr Gastroenterol Nutr. 2005;41:49-55.
21. Katsanos KH, Tatsioni A, Pedersen N, et al. Cancer in inflammatory bowel disease 15 years after diagnosis in a population-based European Collaborative follow-up study. J Crohns Colitis. 2011;5:430-442.
22. Tao B, Pietropaolo M, Atkinson M, et al. Estimating the cost of type 1 diabetes in the U.S.: a propensity score matching method. PLoS One. 2010;5:e11501.
23. Boehncke WH, Menter A. Burden of disease: psoriasis and psoriatic arthritis. Am J Clin Dermatol. 2013;14:377-388.
24. Finkelstein Ea, Trogdon JG, Cohen JW, et al. Annual medical spending attributable to obesity: payer-and service-specific estimates. Health Aff (Millwood). 2009;28:w822-w831.
25. Lennard-Jones JE, Shivananda S. Clinical uniformity of inflammatory bowel disease a presentation and during the first year of disease in the north and south of Europe. EC-IBD Study Group. Eur J Gastroenterol Hepatol. 1997;9:353-359.
26. Dignass A, Eliakim R, Magro F, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. J Crohns Colitis. 2012;6:965-990.
27. Van Assche G, Dignass A, Panes J, et al. The second European evidencebased consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. J Crohns Colitis. 2010;4:7-27.
28. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, practice parameters committee. Am J Gastroenterol. 2010;105:501-523; quiz 524.
29. Lichtenstein GR, Hanauer SB, Sandborn WJ. Management of Crohn's disease in adults. Am J Gastroenterol. 2009;104:465-483; quiz 464, 484.
30. Mowat C, Cole A, Windsor A, et al. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2011;60:571-607.
31. Burisch J, Weimers P, Pedersen N, et al. Health-related quality of life improves during one year of medical and surgical treatment in a European population-based inception cohort of patients with Inflammatory Bowel Disease-An ECCO-EpiCom study. J Crohns Colitis. 2014;8:1030-1042.
32. Cohen RD, Yu a P, Wu EQ, et al. Systematic review: the costs of ulcerative colitis in Western countries. Aliment Pharmacol Ther. 2010;31:693-707.
33. Lakatos PL, Golovics PA, David G, et al. Has there been a change in the natural history of Crohn's disease? Surgical rates and medical management in a population-based inception cohort from Western Hungary between 1977-2009. Am J Gastroenterol. 2012;107:579-588.
34. Odes S, Vardi H, Greenberg D, et al. [P254] Effect of standard treatment (ST) versus episodic (ET) or maintenance (MT) infliximab on healthcare cost (HC) and quality-adjusted life years (QALYs) in a community-based incidence cohort of adult Crohn's disease patients with 10 years followup. J Crohns Colitis. 2012;6:S110-S111.
35. Odes SH, Vardi H, Greenberg D, et al. [Sa1256] cost-effectiveness of episodic or maintenance infliximab treatment versus standard treatment in a community-based incidence cohort of adult ulcerative colitis patients with 10-years follow-up. Gastroenterology. 2012;142:S256.
36. Sprakes MB, Ford AC, Suares NC, et al. Costs of care for Crohn's disease following the introduction of infliximab: a single-centre UK experience. Aliment Pharmacol Ther. 2010;32:1357-1363.
37. Blackhouse G, Assasi N, Xie F, et al. Canadian cost-utility analysis of initiation and maintenance treatment with anti-TNF-a drugs for refractory Crohn's disease. J Crohns Colitis. 2012;6:77-85.